Axsome Therapeutics Reaches Settlement Over Sunosi Patent Dispute; Shares Rise Pre-Bell

MT Newswires Live

06/03

Axsome Therapeutics (AXSM) has settled all patent litigation regarding Sunosi, its treatment for excessive daytime sleepiness, the company said Wednesday.

Under the deal, Axsome said it has granted five companies the right to market generic versions of Sunosi, starting Sept. 1, 2040, if pediatric exclusivity is granted for Sunosi, or on March 1, 2040, if no exclusivity is granted. The settlement is subject to Food and Drug Administration approval and conditions.

The company said no other patent litigation regarding the product remains pending.

Shares of the company were up nearly 9% in Wednesday premarket activity.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2640901083"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640901083\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640901083?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 20:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640901083","market":"us","top_or_hot":-1,"title":"Axsome Therapeutics Reaches Settlement Over Sunosi Patent Dispute; Shares Rise Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (AXSM) has settled all patent litigation regarding Sunosi, its treatment for excessive daytime sleepiness, the company said Wednesday.</p><p>Under the deal, Axsome said it has granted five companies the right to market generic versions of Sunosi, starting Sept. 1, 2040, if pediatric exclusivity is granted for Sunosi, or on March 1, 2040, if no exclusivity is granted. The settlement is subject to Food and Drug Administration approval and conditions.</p><p>The company said no other patent litigation regarding the product remains pending.</p><p>Shares of the company were up nearly 9% in Wednesday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Axsome Therapeutics Reaches Settlement Over Sunosi Patent Dispute; Shares Rise Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAxsome Therapeutics Reaches Settlement Over Sunosi Patent Dispute; Shares Rise Pre-Bell\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-06-03 20:19</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (AXSM) has settled all patent litigation regarding Sunosi, its treatment for excessive daytime sleepiness, the company said Wednesday.</p><p>Under the deal, Axsome said it has granted five companies the right to market generic versions of Sunosi, starting Sept. 1, 2040, if pediatric exclusivity is granted for Sunosi, or on March 1, 2040, if no exclusivity is granted. The settlement is subject to Food and Drug Administration approval and conditions.</p><p>The company said no other patent litigation regarding the product remains pending.</p><p>Shares of the company were up nearly 9% in Wednesday premarket activity.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴資本持倉","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640901083","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640901083","pubTimestamp":1780489192,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Axsome Therapeutics  has settled all patent litigation regarding Sunosi, its treatment for excessive daytime sleepiness, the company said Wednesday.Under the deal, Axsome said it has granted five companies the right to market generic versions of Sunosi, starting Sept. 1, 2040, if pediatric exclusivity is granted for Sunosi, or on March 1, 2040, if no exclusivity is granted. The settlement is subject to Food and Drug Administration approval and conditions.The company said no other patent litigation regarding the product remains pending.Shares of the company were up nearly 9% in Wednesday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4007":"制药","BK4585":"ETF&股票定投概念","AXSM":"Axsome Therapeutics, Inc."},"translate_title":"Axsome Therapeutics就Sunosi专利纠纷达成和解；盘前股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXSM":1.5},"content_text":"Axsome Therapeutics (AXSM) has settled all patent litigation regarding Sunosi, its treatment for excessive daytime sleepiness, the company said Wednesday.Under the deal, Axsome said it has granted five companies the right to market generic versions of Sunosi, starting Sept. 1, 2040, if pediatric exclusivity is granted for Sunosi, or on March 1, 2040, if no exclusivity is granted. The settlement is subject to Food and Drug Administration approval and conditions.The company said no other patent litigation regarding the product remains pending.Shares of the company were up nearly 9% in Wednesday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}